Skip to search formSkip to main contentSkip to account menu

UML-491

Known as: UML 491, UML491 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

MethysergideMethysergide MaleateSerotonin Antagonists

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1971
1971
Action of serotonin on gastric (proventriculus) secretion in chickens.
1965
1965
Antagonism of central effects of tryptamine and 5-hydroxytryptophan by 1,6-dimethyl-8β-carbobenzyloxy-aminomethyl-10α-ergoline
SummaryThe effect of 1,6-dimethyl-8β-carbobenzyloxy-aminomethyl-10α-er-goline (MCE), a potent anti-5-hydroxytryptamine (5-HT… 
1963
1963
EEG study of methysergida in migraine
1962
1962
Vasodilating headache: a suggested classification and results of prophylactic treatment with UML 491 (methysergide).
1962
1962
Vasodilating headache: a suggested classification and results of prophylactic treatment with UML 491 (methysergide).
1961
1961
Treatment of autistic schizophrenic children with LSD-25 and UML-491.
Autistic schizophrenic children present challenging and baffling problems in treatment. Without attempting to deal again with the… 
1961
1961
Contact sensitivity in mice.
1961
1961
Studies on Headache: The Mode of Action of UML-491 and Its Relevance to the Nature of Vascular Headache of the Migraine Type
UML-491, * 1-methyl-D-lysergic acid butanolamide bimaleate, a derivative of lysergic acid, is being extensively investigated as… 
1961
1961
Evaluation of UML-491 in the treatment of vascular headaches. An analysis of the effects of 1-methyl-D-lysergic acid (plus) butanolamide bimaleate (methysergide).
Introduction The chemotherapeutic prevention and treatment of vascular headache of the migraine type has been a troublesome… 
1960
1960
Use of a new compound, UML-491 (1-methyl-D-lysergic acid butanolamide), in the prevention of various types of headache.
IN 1937 Wolff and Graham1 demonstrated that the pain of the migraine attack was associated with dilatation of branches of the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)